Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 8Other solid neoplasm 5Gastrointestinal 5Dermatologic 5Genitourinary 4CNS 3Head & Neck 2Gynecologic 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Endocrine 1Classical hematology 1Breast 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1

Interventions

Dexamethasone 871Bortezomib 457Lenalidomide 456Cyclophosphamide 365Melphalan 272Calcium Dobesilate 263daratumumab 234pomalidomide 208carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74isatuximab 69Cyclosporine 68auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 57Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Semaxinib × Plasma cell × Clear all
NCT00006013 2013-07-11

SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma

Fox Chase Cancer Center

Phase 2 Completed
21 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡